BR100 Increased By (0.93%)
BR30 Increased By (1.42%)
KSE100 Increased By (0.56%)
KSE30 Increased By (0.6%)
BECO 6.09 Increased By ▲ 0.32 (5.55%)
BML 53.40 Increased By ▲ 0.40 (0.75%)
BOP 34.34 Increased By ▲ 0.35 (1.03%)
CNERGY 8.16 Increased By ▲ 0.05 (0.62%)
DCL 12.18 Decreased By ▼ -0.02 (-0.16%)
FCCL 54.10 Increased By ▲ 1.27 (2.4%)
FCSC 5.19 Increased By ▲ 0.12 (2.37%)
FFL 18.10 Increased By ▲ 0.15 (0.84%)
FNEL 1.32 Increased By ▲ 0.03 (2.33%)
HUMNL 10.91 Increased By ▲ 0.03 (0.28%)
KEL 8.14 Increased By ▲ 0.12 (1.5%)
KOSM 5.37 Decreased By ▼ -0.15 (-2.72%)
MLCF 88.10 Increased By ▲ 1.59 (1.84%)
NBP 187.20 Increased By ▲ 2.04 (1.1%)
PACE 10.71 Increased By ▲ 0.13 (1.23%)
PAEL 39.75 Increased By ▲ 0.33 (0.84%)
PIAHCLA 26.25 Increased By ▲ 0.03 (0.11%)
PIBTL 17.43 Increased By ▲ 0.76 (4.56%)
PPL 231.50 Increased By ▲ 3.32 (1.45%)
PRL 35.03 Increased By ▲ 0.35 (1.01%)
PTC 67.52 Increased By ▲ 2.19 (3.35%)
SEARL 91.00 Increased By ▲ 0.87 (0.97%)
SSGC 27.15 Increased By ▲ 0.55 (2.07%)
TELE 8.66 Increased By ▲ 0.38 (4.59%)
THCCL 58.25 Decreased By ▼ -0.25 (-0.43%)
TPLP 8.86 Increased By ▲ 0.64 (7.79%)
TREET 24.60 Increased By ▲ 0.07 (0.29%)
TRG 71.25 Increased By ▲ 1.54 (2.21%)
WAVES 10.00 Increased By ▲ 0.06 (0.6%)
WTL 1.28 No Change ▼ 0.00 (0%)

ISLAMABAD: The Drug Regulatory Authority of Pakistan (DRAP) has issued an immediate recall alert for substandard pharmaceutical products after receiving various complaints from the Directorate of Drug Control (DDC) Punjab.

The DDC Punjab informed the DRAP that the samples of below mentioned product have been reported as “substandard”.

Zaktyl-20 injection For veterinary use only registration No052317 contained of Tylosin Tartrate 230mg/100ml batch umber ZKA077 and produced by M/s Zakfas Pharmaceuticals (Pvt) Ltd 12-Km, Bosan Road, Multan.

Addressing the National Regulatory Field Force of DRAP, provincial drug control departments, healthcare professionals, veterinarians, farmers and consumers, the DRAP has advised the use of substandard veterinary product, can result in therapy failure, increasing the risk of complications and potentially contribute to the development of drug resistance.

The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of the mentioned batch of the product from the market.

The DRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product.

Farmers/consumers should not use this product.

They shall contact their veterinarians or healthcare provider(s) if the animal experienced any problem that may be related to using this product.

Copyright Business Recorder, 2025

Comments

Comments are closed for this article.